Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581144 | 0.80 | HCAR3 (0.56) | HCAR3 | |
| SCHEMBL2792596 | 0.80 | HCAR3 (0.56) | HCAR3 | |
| SCHEMBL29771706 | 0.80 | RAB9A (0.42) | HRH4 | |
| SCHEMBL22057922 | 0.80 | RAB9A (0.42) | HRH4 | |
| SCHEMBL23500917 | 0.79 | ENPP2 (0.48) | GBA1CA1CA2 | |
| SCHEMBL30267549 | 0.77 | HCAR3 (0.58) | HCAR3 | |
| SCHEMBL2792092 | 0.77 | HCAR3 (0.58) | HCAR3 | |
| SCHEMBL22057258 | 0.76 | HCAR3 (0.69) | HCAR3 | |
| SCHEMBL4223820 | 0.76 | HCAR3 (0.40) | HRH4HCAR3 | |
| SCHEMBL27308827 | 0.76 | CCR6 (0.52) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20170183347-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2017-06-29 | — | — | US | disclosed |
| US-9573945-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2017-02-21 | — | — | US | disclosed |
| US-20150166534-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2015-06-18 | — | — | US | disclosed |
| US-8906912-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2014-12-09 | — | — | US | disclosed |
| US-20140051701-A1 | METHODS OF TREATING A DISEASE OR CONDITION OF THE CENTRAL NERVOUS SYSTEM | BIONOMICS LIMITED (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045839-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2014-02-13 | — | — | US | disclosed |
| US-8551990-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2013-10-08 | — | — | US | disclosed |
| US-20130012508-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| US-20130012509-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| EP-2540722-A1 | Novel anxiolytic compounds | Bionomics Limited (AU) | 2013-01-02 | — | — | EP | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 637/4885HRH4 451/4885CA1 987/4885 |
| US-20170183347-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-20130012508-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-20140051701-A1 | METHODS OF TREATING A DISEASE OR CONDITION OF THE CENTRAL NERVOUS SYSTEM | GAP43, PMP22, BDNF | GBA1 62/4885HRH4 1625/4885CA1 506/4885 |
| US-20140045839-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-20150166534-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-20130012509-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | GBA1 618/4885HRH4 442/4885CA1 885/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | GBA1 472/4885HRH4 733/4885CA1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.